Drug-drug  	Drug-drug  	 JJ	B-NP
interactions  	interactions  	 NNS	I-NP
with  	with  	 IN	O
raltegravir  	raltegravir  	 VBG	O
To  	To  	 TO	O
review  	review  	 VB	O
all  	all  	 DT	O
currently  	currently  	 RB	O
published  	published  	 VBN	B-NP
drug-drug  	drug-drug  	 JJ	I-NP
interaction  	interaction  	 JJ	I-NP
studies  	studies  	 NNS	I-NP
with  	with  	 IN	O
the  	the  	 DT	O
HIV-integrase  	HIV-integrase  	 JJ	B-NP
inhibitor  	inhibitor  	 JJ	I-NP
raltegravir 	raltegravir 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
PubMed  	PubMed  	 JJ	B-NP
search  	search  	 NN	I-NP
was  	was  	 VBD	O
conducted  	conducted  	 VBN	O
for  	for  	 IN	O
all  	all  	 DT	O
published  	published  	 JJ	O
reports  	reports  	 NNS	O
up  	up  	 RB	O
to  	to  	 TO	O
August  	August  	 NNP	O
1 	1 	 CD	O
,  	,  	 ,	O
2009  	2009  	 CD	O
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
updated  	updated  	 JJ	O
European  	European  	 JJ	O
and  	and  	 CC	O
US  	US  	 NNP	O
Prescriber 	Prescriber 	 NNP	O
's  	's  	 POS	O
Information  	Information  	 NNP	O
( 	( 	 -LRB-	O
EMEA  	EMEA  	 NNP	B-NP
and  	and  	 CC	O
FDA 	FDA 	 NNP	B-NP
)  	)  	 -RRB-	O
and  	and  	 CC	O
abstracts  	abstracts  	 NNS	O
from  	from  	 IN	O
recent  	recent  	 JJ	O
international  	international  	 JJ	O
scientific  	scientific  	 JJ	B-NP
meetings 	meetings 	 NNS	I-NP
.  	.  	 .	O
A  	A  	 DT	O
total  	total  	 NN	O
of  	of  	 IN	O
14  	14  	 CD	O
drug-drug  	drug-drug  	 JJ	B-NP
interaction  	interaction  	 JJ	I-NP
studies  	studies  	 NNS	I-NP
were  	were  	 VBD	O
found 	found 	 VBN	O
.  	.  	 .	O
Due  	Due  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
relatively  	relatively  	 RB	O
broad  	broad  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
range  	range  	 NN	I-NP
of  	of  	 IN	O
raltegravir  	raltegravir  	 VBG	O
almost  	almost  	 RB	O
all  	all  	 DT	O
co-administered  	co-administered  	 JJ	O
agents  	agents  	 NNS	O
can  	can  	 MD	O
safely  	safely  	 RB	O
be  	be  	 VB	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
raltegravir 	raltegravir 	 NN	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
the  	the  	 DT	O
exception  	exception  	 NN	O
of  	of  	 IN	O
rifampin  	rifampin  	 NN	B-NP
in  	in  	 IN	O
which  	which  	 WDT	O
a  	a  	 DT	O
doubling  	doubling  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
raltegravir  	raltegravir  	 JJ	B-NP
dose  	dose  	 NN	I-NP
to  	to  	 TO	O
800  	800  	 CD	O
mg  	mg  	 JJ	B-NP
BD  	BD  	 NNP	I-NP
is  	is  	 VBZ	O
currently  	currently  	 RB	O
recommended 	recommended 	 VBN	O
.  	.  	 .	O
Raltegravir  	Raltegravir  	 NNP	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
without  	without  	 IN	O
drug-drug  	drug-drug  	 JJ	B-NP
interactions  	interactions  	 NNS	I-NP
but  	but  	 CC	O
due  	due  	 JJ	O
to  	to  	 TO	O
the  	the  	 DT	O
lack  	lack  	 NN	O
of  	of  	 IN	O
an  	an  	 DT	O
effect  	effect  	 NN	O
on  	on  	 IN	O
CYP450  	CYP450  	 NNP	B-NP
or  	or  	 CC	O
UGT  	UGT  	 NNP	B-NP
by  	by  	 IN	O
raltegravir  	raltegravir  	 NN	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
broad  	broad  	 JJ	O
therapeutic  	therapeutic  	 JJ	B-NP
range  	range  	 NN	I-NP
of  	of  	 IN	O
raltegravir  	raltegravir  	 VBG	O
itself 	itself 	 PRP	O
,  	,  	 ,	O
this  	this  	 DT	O
agent  	agent  	 NN	B-NP
can  	can  	 MD	O
safely  	safely  	 RB	O
combined  	combined  	 VBN	O
with  	with  	 IN	O
almost  	almost  	 RB	O
all  	all  	 DT	O
tested  	tested  	 JJ	O
agents 	agents 	 NNS	O
.  	.  	 .	O
